Ceftazidime: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
|drugClass=[[cephalosporin]] | |drugClass=[[cephalosporin]] | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=[[bacterial infections]] of [[gram negative]], [[gram positive]] aerobic bacterias and for [anaerobic bacterias]] | |indication=[[bacterial infections]] of [[gram negative]], [[gram positive]] aerobic bacterias and for [[anaerobic bacterias]] | ||
|adverseReactions=[[diarrhea]] | |adverseReactions=[[diarrhea]] | ||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | ||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
|fdaLIADAdult=*Lower Respiratory Tract Infections: | |||
**[[Pneumonia]]: caused by [[Pseudomonas aeruginosa]] and other [[Pseudomonas spp]].; [[Haemophilus influenzae]], including [[ampicillin-resistant strains]]; [[Klebsiella spp]].; [[Enterobacter spp]]; [[Proteus mirabilis]]; [[Escherichia coli]]; [[Serratia spp]]; [[Citrobacter spp]]; [[Streptococcus pneumoniae]]; and [[Staphylococcus aureus]] ([[methicillin-susceptible strains]]). | |||
*Skin and Skin-Structure Infections: caused by [[Pseudomonas aeruginosa]]; [[Klebsiella spp]].; [[Escherichia coli]]; [[Proteus spp]]., including [[Proteus mirabilis]] and [[indole-positive Proteus]]; [[Enterobacter spp]].; [[Serratia spp]].; [[Staphylococcus aureus]] ([[methicillin-susceptible strains]]); and [[Streptococcus pyogenes]] ([[group A beta-hemolytic streptococci]]). | |||
*[[Urinary Tract Infections]], both complicated and uncomplicated, caused by [[Pseudomonas aeruginosa]]; [[Enterobacter spp]].; [[Proteus spp]]., including [[Proteus mirabilis]] and [[indole-positive Proteus]]; [[Klebsiella spp]].; and [[Escherichia coli]]. | |||
*[[Bacterial Septicemia]] caused by [[Pseudomonas aeruginosa]], [[Klebsiella spp]]., [[Haemophilus influenzae]], [[Escherichia coli]], [[Serratia spp]]., [[Streptococcus pneumoniae]], and [[Staphylococcus aureus]] ([[methicillin-susceptible strains]]). | |||
*Bone and Joint Infections: caused by [[Pseudomonas aeruginosa]], [[Klebsiella spp]]., [[Enterobacter spp]]., and [[Staphylococcus aureus]] ([[methicillin-susceptible strains]]). | |||
*Gynecologic Infections: including [[endometritis]], [[pelvic cellulitis]], and other infections of the female genital tract caused by [[Escherichia coli]]. | |||
*[[Intra-abdominal Infections]], including [[peritonitis]] caused by [[Escherichia coli]], [[Klebsiella spp]]., and [[Staphylococcus aureus]] ([[methicillin-susceptible strains]]) and [[polymicrobial]] infections caused by aerobic and anaerobic organisms and [[Bacteroides spp]] (many strains of [[Bacteroides fragilis]] are resistant). | |||
*Central Nervous System Infections:including [[meningitis]], caused] by [[Haemophilus influenzae]] and [[Neisseria meningitidis]]. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to [[Pseudomonas aeruginosa]] and [[Streptococcus pneumoniae]]. | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ceftazidime in adult patients. | |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Ceftazidime in adult patients. | ||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ceftazidime in adult patients. | |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Ceftazidime in adult patients. | ||
Revision as of 15:05, 13 January 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Ceftazidime is a cephalosporin that is FDA approved for the treatment of bacterial infections of gram negative, gram positive aerobic bacterias and for anaerobic bacterias. Common adverse reactions include diarrhea.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Lower Respiratory Tract Infections:
- Pneumonia: caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp; Proteus mirabilis; Escherichia coli; Serratia spp; Citrobacter spp; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).
- Skin and Skin-Structure Infections: caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).
- Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli.
- Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).
- Bone and Joint Infections: caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).
- Gynecologic Infections: including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.
- Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp (many strains of Bacteroides fragilis are resistant).
- Central Nervous System Infections:including meningitis, caused] by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ceftazidime in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ceftazidime in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Ceftazidime FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ceftazidime in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ceftazidime in pediatric patients.
Contraindications
There is limited information regarding Ceftazidime Contraindications in the drug label.
Warnings
There is limited information regarding Ceftazidime Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Ceftazidime Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Ceftazidime Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Ceftazidime Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Ceftazidime in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ceftazidime in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Ceftazidime during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Ceftazidime in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Ceftazidime in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Ceftazidime in geriatric settings.
Gender
There is no FDA guidance on the use of Ceftazidime with respect to specific gender populations.
Race
There is no FDA guidance on the use of Ceftazidime with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Ceftazidime in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Ceftazidime in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Ceftazidime in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Ceftazidime in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Ceftazidime Administration in the drug label.
Monitoring
There is limited information regarding Ceftazidime Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Ceftazidime and IV administrations.
Overdosage
There is limited information regarding Ceftazidime overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Ceftazidime Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Ceftazidime Mechanism of Action in the drug label.
Structure
There is limited information regarding Ceftazidime Structure in the drug label.
Pharmacodynamics
There is limited information regarding Ceftazidime Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Ceftazidime Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Ceftazidime Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Ceftazidime Clinical Studies in the drug label.
How Supplied
There is limited information regarding Ceftazidime How Supplied in the drug label.
Storage
There is limited information regarding Ceftazidime Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Ceftazidime |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Ceftazidime |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Ceftazidime Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Ceftazidime interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Ceftazidime Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Ceftazidime Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| Directions for use |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]
Overview
Ceftazidime (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negativebacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections.
Category
Cephalosporin, Third-Generation
US Brand Names
FORTAZ®, TAZICEF®, CEFTAZIDIME®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Compatibility and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanism of action
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050578s053,050634s020lbl.pdf